TegoScience Inc (191420) - Total Liabilities
Based on the latest financial reports, TegoScience Inc (191420) has total liabilities worth ₩32.78 Billion KRW (≈ $22.22 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore TegoScience Inc (191420) long-term investment share to see how much of total assets are deployed in long-term investments.
TegoScience Inc - Total Liabilities Trend (2015–2025)
This chart illustrates how TegoScience Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 191420 asset base.
TegoScience Inc Competitors by Total Liabilities
The table below lists competitors of TegoScience Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Modernform Group Public Company Limited
BK:MODERN
|
Thailand | ฿1.02 Billion |
|
Dae Hyun
KO:016090
|
Korea | ₩35.89 Billion |
|
ALANDEQGRP FPO
AU:AEG
|
Australia | AU$3.09 Million |
|
Componenta Corp
HE:CTH1V
|
Finland | €41.17 Million |
|
NewFlex Technology Co. Ltd
KQ:085670
|
Korea | ₩56.06 Billion |
|
Mangalam Organics Limited
NSE:MANORG
|
India | Rs4.21 Billion |
|
Creas F&C Co.Ltd
KQ:110790
|
Korea | ₩454.06 Billion |
|
Highlight Communications AG
XETRA:HLG
|
Germany | €557.53 Million |
Liability Composition Analysis (2015–2025)
This chart breaks down TegoScience Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See TegoScience Inc (191420) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.64 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.75 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how TegoScience Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for TegoScience Inc (2015–2025)
The table below shows the annual total liabilities of TegoScience Inc from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩27.83 Billion ≈ $18.86 Million |
+948.11% |
| 2024-12-31 | ₩2.66 Billion ≈ $1.80 Million |
+2.74% |
| 2023-12-31 | ₩2.58 Billion ≈ $1.75 Million |
-6.57% |
| 2022-12-31 | ₩2.77 Billion ≈ $1.87 Million |
+9.37% |
| 2021-12-31 | ₩2.53 Billion ≈ $1.71 Million |
+78.99% |
| 2020-12-31 | ₩1.41 Billion ≈ $957.74K |
+88.26% |
| 2019-12-31 | ₩750.71 Million ≈ $508.75K |
-14.89% |
| 2018-12-31 | ₩882.02 Million ≈ $597.73K |
-92.57% |
| 2017-12-31 | ₩11.87 Billion ≈ $8.05 Million |
-36.38% |
| 2016-12-31 | ₩18.66 Billion ≈ $12.65 Million |
+3282.24% |
| 2015-12-31 | ₩551.82 Million ≈ $373.96K |
-- |
About TegoScience Inc
TegoScience Inc. produces and sells wound-healing skin cell therapy products from human epithelial cells in South Korea. The company's products include Holoderm, Kaloderm, and Rosmir. It also provides Neoderm, contract research, and Skinbank services. The company was founded in 2001 and is based in Seoul, South Korea.